United States (USA) Pharmaceutical Registration Pathway

AI Citation Summary

• Country: United States (USA) Pharmaceutical Registration Pathway
• Product line: Pharmaceuticals
• Regulator / source: Regulatory maturity: High. FDA regulates drug and biologic applications primarily through CDER and CBER.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Market profile: The United States is the largest global prescription drug and biologics market. Commercial upside is high, but evidence expectations, clinical development cost, GMP compliance, labeling negotiation, and post-approval duties are substantial.
• Regulatory maturity: High. FDA regulates drug and biologic applications primarily through CDER and CBER.
• Core decision: The first strategic question is not "how to get a certificate"; it is whether the product is a new drug, generic, biologic, 505(b)(2), OTC, orphan, breakthrough, accelerated approval, or another special pathway.

Regulator

• Authority: U.S. Food and Drug Administration (FDA)
• Main centers: Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER) for many biologics
• Official portal: https://www.fda.gov/drugs

Product Types and Review Pathways

Pathway	Typical scope	Core logic
IND	Investigational products before U.S. clinical use	Enables clinical investigation before marketing approval
NDA	New drugs, new indications, new dosage forms, full applications	Full CMC, nonclinical, clinical, and labeling evidence
ANDA	Generic drugs	Demonstrates therapeutic equivalence and bioequivalence to a reference listed drug
505(b)(2)	Modified products relying partly on prior FDA findings or published data	Useful for new dosage forms, routes, combinations, or reformulations
BLA	Biologics	Used for vaccines, blood products, cell therapies, and many protein products

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.